• Pfizer beats back generic competition for Lyrica Thursday, 6 Feb 2014 | 1:01 PM ET

    WASHINGTON, Feb 6- Pfizer Inc, the world's largest drugmaker, has beaten back generic competition for the pain medicine Lyrica, its biggest product, with a U.S. appeals court ruling that competing generic products would infringe on the company's patents.

  • MUMBAI/ LONDON, Feb 6- Global pharmaceutical firms are pressuring the United States to act against India to stop more local companies producing up to a dozen new varieties of cheap generic drugs still on-patent, sources with direct knowledge of the matter said.

  • Feb 5- A U.S. judge on Wednesday declared a mistrial in a lawsuit brought by private patent owner Intellectual Ventures against Google Inc's Motorola Mobility unit after jurors could not unanimously agree, according to an Intellectual Ventures statement.

  • Adidas sues Under Armour over patent infringement Tuesday, 4 Feb 2014 | 11:29 PM ET

    Feb 4- German sportswear maker Adidas sued Under Armour Inc in a U.S. court over alleged infringement of patents governing fitness training and tracker devices, a court filing showed. In a lawsuit filed with the Delaware court on Tuesday, Adidas said Under Armour and MapMyFitness "willfully infringed" the German company's ten patents.

  • Twitter buys patents, seals licensing pact with IBM Friday, 31 Jan 2014 | 9:00 AM ET

    SAN FRANCISCO, Jan 31- Twitter Inc has bought 900 patents and signed a cross-licensing agreement with IBM, making peace with Big Blue and bulking up on its intellectual property portfolio as it takes on larger rivals Google and Facebook.

  • *Sanofi alleges Lilly infringed four patents. *Sanofi, Novo shares rise on delayed biosimilar threat. NEW YORK/ PARIS, Jan 31- French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. firm's plans to produce a copycat version of Lantus.

  • Jan 30- French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus.

  • STOCKHOLM, Jan 27- Samsung Electronics Co will pay Ericsson $650 million along with years of royalties to end a technology licence spat, the Swedish company said on Monday. The initial payment will lift fourth-quarter sales by 4.2 billion Swedish crowns and net income by 3.3 billion, Ericsson said in a statement.

  • STOCKHOLM, Jan 27- Ericsson said on Monday it had signed a cross- licensing deal with Samsung Electronics Co, ending a long-running patent dispute and boosting fourth-quarter sales by 4.2 billion crowns.

  • Kasim Alfalahi, chief intellectual property officer at Ericsson, says that the resolution of the patent dispute between Samsung and Ericsson is good for the technology industry.

  • Google, Samsung announce global patent agreement Sunday, 26 Jan 2014 | 4:00 PM ET

    Jan 26- Google Inc and Samsung Electronics Co Ltd, which are frequently involved in patent infringement lawsuits but not against each other, announced on Sunday that they have reached a global patent cross-licensing agreement.

  • WILMINGTON, Del., Jan 23- Opening statements began on Thursday in patent owner Intellectual Ventures' trial against Google's Motorola Mobility unit in a lawsuit that could be a bellwether on public opinion toward intellectual property.

  • Jan 23- Chipmaker Qualcomm Inc acquired a patent portfolio from Hewlett-Packard Co, including those of Palm Inc and its iPaq smartphone, in a move that will bulk up HP's offerings to handset makers and other licensees.

  • Qualcomm acquires patent portfolio from HP Thursday, 23 Jan 2014 | 5:02 PM ET

    Jan 23- Chipmaker Qualcomm Inc acquired a patent portfolio from Hewlett-Packard Co, including those of its iPaq smartphone, for an undisclosed amount. The portfolio comprises about 1,400 granted patents and pending patent applications from the United States and about 1,000 granted patents and pending patent applications from other countries.

  • Momentum continues for Amazon: Analyst     Tuesday, 21 Jan 2014 | 2:16 PM ET

    Amazon has filed a patent for its "anticipatory shipping" process. Ben Schachter, analyst for Macquarie Capital, thinks Amazon will continue to excel against its competitors. CNBC's Jon Fortt, weighs in.

  • Amazon files patent to anticipate your orders     Tuesday, 21 Jan 2014 | 12:45 PM ET

    Discussing news Amazon has filed a patent for an "anticipatory shipping" process, with the FMHR traders.

  • SAN FRANCISCO, Jan 20- Intellectual Ventures is set to square off this week against Google Inc's Motorola Mobility unit in the first trial that the multibillion-dollar patent-buying firm has undertaken since it was founded.

  • Jan 15- A U.S. jury strengthened Edwards Lifesciences Corp's efforts to protect sales of the company's transcatheter heart valve implants, by ruling that a competing product from Medtronic Inc infringes its patent.

  • SAN FRANCISCO Jan 14- A Texas judge has upheld U.S. patents covering Allergan Inc's Lumigan glaucoma drug through 2027, the company said in a regulatory filing on Tuesday, helping to send its shares up 6 percent.

  • Teva did not infringe OxyContin patents, shares rise Tuesday, 14 Jan 2014 | 5:43 PM ET

    Jan 14- A federal judge said Teva Pharmaceutical Industries Ltd did not infringe five patents related to the painkiller OxyContin, helping push shares of the world's largest generic drug manufacturer up 6.7 percent on Tuesday.

Most Popular Video

Wednesday, 16 Apr 2014 | 10:41 AM ET

CNBC's Dominic Chu digs into the year-to-date S&P performance of the airlines and explains why it has been the lone bright spot for the industrial sector.

Wednesday, 16 Apr 2014 | 4:03 PM ET

Providing instant analysis to Google's quarterly numbers, with Victor Anthony, Topeka Capital Markets; Andrew Stoltmann of Stoltmann Law Offices; CNBC contributor Michael Yoshikami; "Fast Money" trader Tim Seymour; CNBC's Michelle Caruso-Cabrera and Dominic Chu.

Wednesday, 16 Apr 2014 | 12:35 PM ET

Intel CEO Brian Krzanich discusses some signs of stability in enterprise in the mature markets, and whether the emerging markets area steadying as well.